On July 20, 2026, Seer, Inc. announced that a Special Committee of its Board of Directors unanimously rejected an unsolicited, non-binding proposal from Chair and CEO Omid Farokhzad, M.D., received on July 1, 2026. The proposal sought to acquire all outstanding Class A common stock for $2.45 per share in cash plus two contingent value rights. The Special Committee determined the offer undervalued the company and its long-term growth prospects. Seer operates in the biotechnology industry, providing a proteomic product suite for deep, unbiased proteomics research.
